Abstract Owing to its cytotoxicity, free copper is chelated by protein side chains and does not exist in vivo.
Introduction
Copper is a vital micronutrient and is essential for the activity of multiple enzymes in the cell, such as cytochrome c, superoxide dismutase, and lysyl oxidase [1] . Owing to its cytotoxicity, free copper essentially does not exist in vivo, as it is chelated through side chains on proteins [2] .
Copper-64 (t 1/2 = 12.7 h, b ? 0.655 MeV, 17.8 %; b -0.573 MeV, 41 %) is a b ? and b -emitter, making it an ideal radionuclide for positron emission tomography (PET) and targeted radionuclide therapy. For example, copper radiopharmaceuticals have been widely investigated for PET, both in animal models and in humans [3] . Therapeutic efficacy of 64 Cu radiopharmaceuticals in rat and hamster models was demonstrated with 64 Cu-labeled somatostatin analogs and monoclonal antibody (mAb) conjugates, respectively [4, 5] . Moreover, enhanced therapeutic efficacy of an internalizing 64 Cu-labeled mAb, 64 Cu-BAT-2IT-IA3, in a tumor-bearing hamster model was observed compared with the therapeutic efficacy in published studies of 131 I-or 90 Y-labeled mAbs in the same animal model [6] . Wang et al. [7] found the nuclear uptake of 64 Cu from 64 Culabeled 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) octreotide localized in the nucleus to a greater extent than that of 111 In from 111 In-labeled diethylenetriaminepentaacetic acid (DTPA) octreotide.
Copper binds to DNA and has been suggested to play an important role in DNA folding and repair [8] . Chui et al. [9, 10] found that treatment of isolated nuclei with unlabeled Cu 2? enhanced DNA cross-linking to nuclear matrix proteins on irradiation, and that Cu 2? can cause additional damage to DNA and/or nuclear proteins by producing free radicals at copper binding sites. Because the delivery of 64 Cu to the cell nucleus may enhance the therapeutic effect of b -and low energy electron emitting tumor targeting copper radiopharmaceuticals, elucidating the pathway(s) involved in transporting copper to the nucleus is important for optimizing therapy.
Multiple studies have been performed to evaluate the cellular transport of copper. Copper enters cells through the human copper transporter 1 (Ctr1) and is delivered to different compartments [11] . Several copper-binding proteins and chaperones have been identified, including metallothionein, Cox17, and Atox1, which are involved in copper storage, transport to the mitochondria, and transport to the Golgi apparatus [1, [11] [12] [13] . To date, there is no definitive evidence for a chaperone that transports copper to the cell nucleus.
Cisplatin is a potent chemotherapeutic agent. Multiple lines of evidence indicate that the mechanism of transport of cisplatin into the cell and its distribution to different cell compartments involves copper transporters [14] . Cisplatin binds to the metal binding site of Atox1, as well as to copper-loaded Atox1, without loss of copper [15, 16] . A relationship between nuclear transport of copper and cisplatin may exist, but to our knowledge has not yet been reported. After nuclear transport, cisplatin cross-links DNA to interrupt transcription and cell replication, resulting in cell death [17, 18] .
The tumor suppressor protein p53 plays a major role in the cell stress response. When activated, p53 accumulates in the nucleus to increase transcription and activation of proteins involved in DNA repair and/or apoptosis. For example, cisplatin treatment of HCT 116 colorectal cancer cells results in p53 activation, leading to p38 mitogenactivated protein kinase activation and resulting in apoptosis [19] . We previously demonstrated that HCT 116 p53
?/? cells accumulate more copper in their nuclei than HCT 116 p53 -/-cells, suggesting a role for p53 in the transport of 64 Cu to the nucleus [20] . The purpose of the current study is to elucidate the mechanism of copper transport into the nucleus. Here, we present data suggesting that Atox1 is one of the proteins involved in the transport of copper to the nucleus, and that p53 influences the nuclear copper transport by affecting the regulation of Atox1 expression. Our data also demonstrate that cisplatin enhances the copper transport to the nucleus of HCT 116 cells by upregulating Atox1 and increasing its nuclear localization.
Materials and methods

Reagents
Copper-64 (t 1/2 = 12.7 h; b ? , 17.8 %, Ebþ max = 0.655 MeV; b -, 38.4 %, EbÀ max = 0.573 MeV) was obtained from Washington University (St. Louis, MO, USA) and the University of Wisconsin (Madison, WI, USA). All chemicals and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise specified. Cell culture media were purchased form Invitrogen (Grand Island, NY, USA). Cisplatin was purchased from Sigma-Aldrich (St. Louis, MO, USA). Aqueous solutions were prepared using ultrapure water (resistivity, 18 MX cm). Mouse anti-human p53 and mouse anti-bactin were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse anti-human p53 (PAb240) and mouse anti-human Atox1 were purchased from Abcam (Cambridge, MA, USA), and mouse anti-human TATAbinding protein was purchased from Pierce (Rockford, IL, USA).
Isolation and identification of the copper-binding partner from HCT 116 cells Cells were pretreated with cisplatin (40 lM) for 24 h and incubated with [
64 Cu]copper acetate (300 lCi) for another 24 h. Nuclear fractions were collected as previously described [7] . Nuclear pellets were sonicated for 30 s and spun down to obtain the supernatants. Size-exclusion highperformance liquid chromatography (HPLC) was used to separate the copper-binding partner from the supernatant. The sample was run on a Superose 12 HR 10/300 column (Amersham Biosciences, Piscataway, NJ, USA) for 60 min and detected with an ORTEC model 661 radioactive detector (EG&G Instruments). The mobile phase was 0.15 M NaCl and 20 mM N-(2-hydroxyethyl)piperazine-N 0 -ethanesulfonic acid (pH 7.3) with a flow rate of 0.5 mL/ min. One sample was collected per minute and a Beckman 8000 gamma counter was used to count the radioactivity in the size-exclusion HPLC fractions. Fractions with high counts were collected and placed in a SpeedVac (Thermo Scientific, Waltham, MA, USA) to reduce the volume to approximately 20-30 lL. Samples were reconstituted in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer and loaded onto Criterion XT 4-12 % precast gels (Bio-Rad, Hercules, CA, USA). The gels were then silver-stained, and identified bands were isolated and subjected to trypsinization as previously described [21] . Fragments were analyzed by matrix-assisted laser desorption ionization mass spectrometry, ABI 5600 (Applied Biosystems, Grand Island, NY, USA) at the National Institutes of Health/National Center for Research Resources mass spectrometry facility at Washington University. Identified sequences were screened with the National Center for Biotechnology Information Uniprot database.
Cell culture
Human colorectal tumor (HCT 116) p53
?/? and p53
-/-cells (provided by Bert Vogelstein, Johns Hopkins University) were cultured in McCoy's 5A medium supplemented with 10 % fetal bovine serum, penicillin (100 U/ mL), streptomycin (100 lg/mL), and L-glutamine (300 lg/ mL), and immortalized mouse embryonic fibroblast (MEF) Atox1 ?/? and Atox1 -/-cells (provided by Stephen Howell, University of California, San Diego, through Jonathan Gitlin) were cultured in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum, penicillin (100 U/mL), streptomycin (100 lg/mL), L-glutamine (300 lg/mL), sodium pyruvate (100 mg/mL), and glucose (4.5 g/L). All tissue culture media and supplements were obtained from Invitrogen (Grand Island, NY, USA).
Nuclear localization and internalization of [
64 Cu]copper acetate in HCT 116 and MEF cell lines HCT 116 and MEF cell nuclei were collected as previously described by Wang et al. [7] Experiments were performed in six-well plates containing approximately 1.5 9 10 6 cells at the beginning of the time course. [
64 Cu]copper acetate (50 lCi) was added, and after incubation for 2, 6, and 24 h, the cells were pelleted, resuspended in cytoskeletal (CSK) buffer/0.5 % Triton X100 [1 mM ethylene glycol bis(2-aminoethyl ether)tetraacetic acid, 2 mM MgCl 2 , and 10 mM piperazine-1,4-bis(2-ethanesulfonic acid), 0.5 % Triton X100, pH 6.8], and incubated on ice for 2 min. Cell lysates were centrifuged at 560g for 5 min at 4°C, and the supernatant was discarded. The nuclear pellet was resuspended in 4 mL CSK buffer without Triton X-100, and was centrifuged at 560g at 4°C for 5 min. The supernatant was discarded and the nuclear pellet was counted with a gamma counter. The yield of nuclei was determined by counting the initial number of cells (stained with trypan blue) and the collected nuclei (stained with crystal violet) using a hemocytometer. The percentage of 64 Cu in the cell nuclei was determined by the counts per minute in the pure nuclei divided by the counts per minute for 64 Cu internalized in whole cells, and was corrected for the yield of nuclei or for the amount of protein. 
Western blot
Cells were harvested with trypsin, pelleted by centrifugation at 1,500 rpm at 4°C, and solubilized with radioimmunoprecipitation assay lysis buffer (Pierce, Rockford, IL, USA) containing protease inhibitors (cOmplete, mini; Roche, Indianapolis, IN, USA) for 20 min on ice. The cells were then centrifuged at 14,500 rpm for 15 min, the pellet was discarded, and the supernatant was assayed for protein concentration using the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Electrophoresis was performed under denaturating conditions with 20-35 lg protein per lane (100 lg protein was loaded per lane in nuclear fraction Western blots) on 4-20 % TGX precast gels (Bio-Rad, Hercules, CA, USA) using a Bio-Rad Mini electrophoresis system. The proteins were transferred to a nitrocellulose membrane (Trans-Blot mini membranes; Bio-Rad, Hercules, CA, USA) using a Trans-Blot Turbo system (BioRad, Hercules, CA, USA). Blots were saturated in 5 % dry nonfat milk in tris(hydroxymethyl)aminomethane-buffered saline/Tween 20 buffer (Bio-Rad) for 30 min at room temperature. The blots were incubated with primary antibodies (1 lg/mL) in 5 % milk/tris(hydroxymethyl)aminomethane-buffered saline/Tween 20 buffer overnight at 4°C, followed by incubation with horseradish-peroxidaseconjugated secondary antibodies (Bio-Rad, Hercules, CA, USA) for 1 h at room temperature. The blots were exposed to electrochemiluminescence reagents (Immobilon Western; Millipore, Billerica, MA, USA) and detected on X-ray films or using a gel imager (ChemiDoc MP; Bio-Rad, Hercules, CA, USA). Western blot relative quantification was realized using the computer program Image Lab from Bio-Rad by calculating the ratio of the integrated intensity of the band of the protein of interest to the integrated intensity of the b-actin band.
Small interfering RNA knockdown of p53 in the MEF cell line MEF cells were seeded in six-well plates or on glass coverslips in 24-well plates to attain 20-30 % confluence after 24 h. The transfection was done with p53 siRNA (Santa Cruz Biotechnology, Dallas, TX, USA) using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions (20 pmol siRNA). The transfection mixture was added to the cells, and after 5 h fresh medium was added. Cells were assayed 48 h after transfection.
Small interfering RNA knockdown of Atox1 in the HCT 116 cell line HCT 116 p53 ?/? and p53 -/-cells were seeded in six-well plates to attain 30-40 % confluence after 24 h. The transfection was performed with Atox1 siRNA (OriGene, Rockville, MD, USA) using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions (80 pmol siRNA). The transfection mixture was added to the cells, and after 5 h fresh medium was added. Cells were assayed 48 h after transfection.
Immunofluorescence and confocal microscopy HCT 116 p53
?/? and p53 -/-cells or MEF Atox1 ?/? cells were seeded on glass coverslips in a 24-well plate and left to adhere overnight. Cells were then fixed with 4 % paraformaldehyde in phosphate-buffered saline (PBS) for 15 min at room temperature and permeabilized with 0.2 % Triton X-100 in PBS for 5 min at room temperature. After the washing with PBS, nonspecific binding was saturated with 0.1 % bovine serum albumin (BSA) for 30 min. Mouse antihuman Atox1 (Abcam, Cambridge, MA, USA) (1:200 dilution in PBS/0.1 % BSA) or goat anti-mouse HAH1 (Santa Cruz Biotechnology, Dallas, TX, USA) (1:200 dilution in PBS/0.1 %BSA) and rabbit anti-human p53 antibody (Cell Signaling Technology, Danvers, MA, USA) (1:200 dilution in PBS/0.1 %BSA) were added for 1 h at room temperature, followed by addition of a secondary antibody-anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 594 (Invitrogen, Grand Island, NY, USA), or antigoat Alexa Fluor 564 (1:400 dilution in PBS/0.1 %BSA)-for 1 h at room temperature. After they had been washed in PBS, the coverslips were mounted using ProLong antifading medium (Invitrogen, Grand Island, NY, USA). Immunofluorescence staining was monitored using a Zeiss Apotome system equipped with a Zeiss HPO PL APO 940 or 963 oil immersion lens (numerical aperture 1.4-0.6). All comparable images were taken with the same exposure time. Fluorescence quantification was done using AutoQuant X3, and the regions of interest were drawn around the cells, and the sum of the total voxel intensity was measured for each cell. A total of 35 cells from three different slides per cell line and per treatment condition were compared. Colocalized images were generated using AutoQuant X3; the colocalization gate was the same for all images, and both the Menders and Pearson's correlation indices were greater than 0.9. Integrated density calculation was done using ImageJ.
Statistical analysis
All data are presented as the mean ± the standard deviation. Groups were compared using a two-tailed Student t test. Values of p below 0.05 were considered statistically significant.
Results
Identification of the protein that binds
64 Cu in the nucleus of HCT 116 cells In previous studies, Eiblmaier et al. [20] -/-cells (5.5 ± 0.6 %ID/mg vs 4.9 ± 0.5 %ID/ mg); however, at later times the Atox1 -/-cells accumulated significantly more 64 Cu than the Atox1
?/? cells (n = 3, p \ 0.05). At 6 and 24 h, 64 Cu uptake in Atox1
?/? cells was 6.8 ± 1.3 and 12.8 ± 0.6 %ID/mg, respectively, and Atox1
-/-cells accumulated 10.6 ± 1.2 and 15.9 ± 1.0 %ID/mg, respectively (Fig. 1a) . This difference was similar to that previously reported [22, 23] -/-cells) (Fig. 1b) . These results suggest that Atox1 plays a major role in the transport of copper to the nucleus.
Atox1 expression in HCT 116 cells
To investigate potential differences in Atox1 expression between HCT 116 p53 ?/? and p53 -/-cells, Western blot analysis was performed. The Atox1 ratio (n = 3) was normalized to b-actin, with a value of 1.1 ± 0.1 for HCT 116 p53 -/-cells (Fig. 2) . These results suggest that p53 also plays a role in the regulation of Atox1 expression. -/-cells (Atox1-siRNAtreated, 0.63 ± 0.11 %ID per nucleus; nontreated, 0.32 ± 0.01 %ID per nucleus; p \ 0.05) (Fig. 3a) . These results are in strong correlation with the results obtained in MEF cells and confirm the importance of Atox1 in copper transport to the nuclei. ?/? cells using siRNA. The expression of Atox1 was evaluated by immunofluorescence and the results show that the knocked down MEF cells overexpressed Atox1 (Fig. 4a) -/-cells after p53 knockdown was also evaluated, and higher nuclear localization of 64 Cu was observed in MEF Atox1
?/? cells treated with p53 siRNA compared with the control (p53-siRNA-treated, 4.77 ± 0.7 %ID per nucleus; nontreated, 3.33 ± 0.3 %ID per nucleus; p = 0.057) (Fig. 4c) ?/? cells pretreated with cisplatin internalized twofold less 64 Cu than nontreated cells (cisplatintreated, 10.7 ± 0.6 %ID/mg; nontreated, 22.6 ± 0.7 %ID/ mg), which is likely due to the downregulation of human Ctr1 by cisplatin [24] [25] [26] . Internalization of 64 Cu in HCT 116 p53 -/-cells was not affected by cisplatin treatment (cisplatin-treated, 26.0 ± 1.1 %ID/mg; nontreated, 27.0 ± 0.7 %ID/mg) (Fig. 5a ). The pretreatment with cisplatin increased the nuclear localization of 64 Cu in both HCT 116 p53
?/? and HCT 116 p53 -/-cells. In the p53
?/?
cells pretreated with cisplatin, the level of nuclear 64 Cu is approximately 3.5-fold higher than in nontreated cells (26.5 ± 4.2 %ID/mg vs 7.4 ± 0.1 %ID/mg, respectively; p \ 0.001), whereas in HCT 116 p53
-/-cells pretreated with cisplatin, the level of 64 Cu in the nuclei is approximately 1.4-fold higher than in nontreated cells (9.7 ± 0.3 %ID/mg vs 7.1 ± 0.1 %ID/mg, respectively; p \ 0.05) (Fig. 5b) . A longer incubation with [
64 Cu]copper acetate was not possible owing to the high mortality of the cells pretreated with cisplatin (more than 80 %).
Effect of cisplatin on the expression and localization of Atox1 in HCT 116 cells
The data indicate that cisplatin impacts internalization and the nuclear localization of 64 Cu in HCT 116 cells, with differing effects between p53
?/? and p53 -/-cells. In addition, the data suggest that Atox1 plays an important (Fig. 6a, d) . Fluorescence quantification shows an approximately twofold increase in the level of Atox1 in cells incubated with cisplatin, with a small but significant difference between p53 ?/? and p53 -/-cells (Fig. 6b, e) . The Western blot results correlate with the data obtained from immunofluorescence and confirm that cisplatin increases the expression of Atox1 (Fig. 6c, f) . In addition, the confocal images showed greater staining for Atox1 in the nuclei of HCT 116 p53
?/? and p53 -/-cells treated with cisplatin compared with nontreated cells. Colocalization of Atox1 and 4 0 ,6-diamidino-2-phenylindole (DAPI) staining of the nuclei clearly show that Atox1 translocates to the nucleus in HCT 116 p53
-/-cells treated with cisplatin, with higher colocalization in HCT 116 p53 ?/? cells (Fig. 7a, b) . These data correlate with the results from Western blot analysis that also show an increase in the level of nuclear Atox1 after treatment with cisplatin, with a higher increase of Atox1 levels in HCT 116 p53
?/? cells compared with HCT 116 p53
-/-cells (Fig. 7c) .
Discussion
Copper homeostasis has been well studied, and significant progress has been made to identify the chaperones and proteins that bind and transport copper to different compartments of the cell; however, to date there is no clear evidence for chaperones that transfer copper to the cell nuclei. This study provides the first evidence that Atox1 is one of the proteins that plays a role in the transport of copper to the cell nuclei. After treatment of HCT 116 cells with [ 64 Cu]copper acetate, mass spectrometry of the nuclear fractions containing 64 Cu showed that Atox1 is one of the proteins in these fractions. Our results show that MEF Atox1
?/? cells accumulate more copper in their nuclei compared with cells that lack Atox1, suggesting a role of Atox1 in the transport and accumulation of copper in the cell nuclei. Knockdown of Atox1 in HCT 116 p53
?/? and p53 -/-cells decreased the nuclear localization in both types of cells, which confirms our observation in MEF cells that Atox1 plays a role in the transport of copper to the nucleus. Itoh et al. [27] identified Atox1 as a copper-dependent transcription factor involved in cell proliferation and showed that Atox1 undergoes nuclear translocation when activated by copper. These data obtained by Itoh et al. are consistent with our results that indicate Atox1 transports copper to the cell nuclei. In addition, the data presented here show that although internalization of 64 Cu was greater in Atox1 -/-cells, nuclear localization was significantly higher in Atox1
?/? cells (Fig. 1) , suggesting a role of Atox1 for binding copper in the cytoplasm via the CXXC motif and transporting it to the nucleus. It should be noted that our data contradict the findings in a report by McRae et al. [28] , where quantitative synchrotron X-ray fluorescence data suggested that MEF Atox1
-/-cells accumulate more copper in the nuclei compared with MEF Atox1
?/? cells. The discrepancy may be explained by the fact that the analysis of the copper distribution in the cells done by McRae et al. was performed on 2D fluorescence images and was limited to only three cells, whereas the experiments described here were performed with large numbers of cells (more than 10 6 for each condition and/or treatment). Additionally, the relative amount of copper in cells was determined directly using a highly accurate tracer technique ( 64 Cu), and all experiments were performed in triplicate. Greater copper accumulation (internalization) over time was found in MEF Atox1
-/-cells than in MEF Atox1
cells; however, the nuclear accumulation of copper was much higher in Atox1 ?/? cells. Miyayama et al. [29] demonstrated that knocking down Atox1 in metallothionein-knockout MEF cells increased the concentration of the copper influx pump, Ctr1, and copper chaperone Ccs, which is consistent with the greater accumulation of copper over time in Atox1
-/-cells than in Atox1
?/? cells. In addition, studies have shown that Atox1 is important for the efflux of copper from cells [30] .
We previously showed that p53 plays a role in copper transport to the nuclei of HCT 116 cells [20] . As a crucial transcription factor, p53 affects many cellular processes and regulates the expression of several proteins [31] . Our results suggest that p53 may affect nuclear transport of copper by increasing the Atox1 expression level. Interestingly, the level of Atox1 in HCT 116 p53-knockout cells is less than that in HCT 116 p53
?/? cells (Fig. 2) . In contrast, p53 knockdown in MEF cells resulted in overexpression of Atox1. These conflicting results indicate that the effect of p53 on Atox1 expression is cell-line-dependent and complex, with potential mediators also playing a role between p53 and Atox1 expression. Despite the differences in the effect of p53 on Atox1 expression observed between the HCT 116 and MEF cell lines, the correlation between cellular Atox1 levels and nuclear localization of 64 Cu was consistent between both cell lines. Increased nuclear localization of copper was observed with higher Atox1 protein expression, suggesting that Atox1 plays a significant role in the transport copper to the cell nuclei.
There has been ongoing interest in targeted radionuclide therapy over the past few decades, as it may improve tumor killing with less toxicity than chemotherapeutic agents. In addition to decaying by b ? emission for PET,
64
Cu decays by b -and Auger electron emission, leading to tumor cell DNA damage that may enhance cancer therapy. Understanding the mechanism of transport of copper to tumor cell nuclei and how platinum chemotherapy affects this transport is of great importance for combining chemotherapy with targeted radiotherapy with 64 Cu-based agents for cancer treatment. It is known that cisplatin binds to DNA and induces cell death. There is evidence that Ctr1 contributes to the transport of cisplatin into cells [14, [32] [33] [34] . Here we studied the effect of cisplatin on copper internalization and nuclear localization in HCT 116 p53
?/? and p53 -/-cells. Cells were pretreated with cisplatin for 24 h prior to incubation with 64 Cu, and cisplatin reduced the copper uptake in HCT 116 p53
?/? cells, possibly owing to the downregulation of Ctr1 by cisplatin. Copper internalization in HCT 116 p53 -/-cells was not affected by cisplatin treatment possibly because the lack of p53 may disrupt the mechanism by which cisplatin downregulates Ctr1. However, cisplatin significantly increased nuclear localization of 64 
Cu in p53
?/? cells, whereas in p53 -/-cells there was only a modest but significant increase. Greater nuclear localization of copper after treatment with cisplatin is likely due to the upregulation of Atox1 by cisplatin. Our data show that cisplatin increases expression of Atox1 in both p53
?/? and p53 -/-cells, but to a higher extent in p53
?/? cells (Fig. 6 ). In addition, after treatment with cisplatin, Atox1 colocalizes more in the nuclei of HCT 116 p53
?/? cells than in the nuclei of HCT 116 p53 -/-cells as shown by immunofluorescence and Western blot (Fig. 7) . This finding is consistent with the nuclear localization results and also supports our hypothesis that Atox1 transports copper to nuclei. In addition, we observed a higher amount of nuclear copper in HCT 116 p53
?/? cells than in HCT 116 p53
-/-cells. Studies have shown that apoptosis increases the nuclear envelope permeability [35, 36] . HCT 116 p53
?/? cells are more sensitive to cisplatin than HCT 116 p53 -/-cells and undergo much more apoptosis and cell death, which may increase their nuclear permeability and explains the higher amount of copper and Atox1 in the nuclei of p53
?/? cells compared with p53
-/-cells.
In conclusion, we have demonstrated that Atox1 plays a significant role in the transport of copper into the nucleus.
Cisplatin upregulates Atox1 and increases its localization to the nuclei. The nuclear localization of Atox1 correlates with nuclear localization of 64 Cu. The data presented here provide insights into combining platinum drug therapy and 64 Cu targeted radiotherapy for cancer. Increased nuclear localization of 64 Cu after cisplatin treatment may increase DNA damage in cancer cells and enhance cell killing by 64 Cu. Combining chemotherapy and targeted radiotherapy could also help reduce the dose of chemotherapy drugs, and thereby decrease their side effects, improving quality of life for cancer patients. The combination of 64 Cu and cisplatin may also improve the efficiency of treating resistant tumors that have wild-type p53.
